Price History

Hover for the daily close. The dotted line marks the period open.

Compare CABA with… →

CABA Key Statistics

As of Sep 4, 2026

Trading

Open: $3.46
Previous Close: $3.48
Day's Range: 3.40–3.60
52-Week Range: 1.63–4.23
Volume: 4.86M
Beta: 3.26

Valuation

Market Cap: $588.32M
P/E Ratio: unprofitable
EPS (ttm): −1.38

Financials (FY)

Revenue (FY): $0.00
Net Income (FY): −$167.86M
Profit margin: 0.00%
Shares Outstanding: 169.55M
1-Year Return: +125.32%

Dividend and dates

Earnings Date: November 16, 2026estimated
Avg Volume: 4.83M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

CABA Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

+39.70%−10.67%−69.63%+144.06%+145.41%−90.00%−3.52%+58.45%

2019*2020202120222023202420252026*

Year	Return
2026 (partial year)	+58.45%
2025	−3.52%
2024	−90.00%
2023	+145.41%
2022	+144.06%
2021	−69.63%
2020	−10.67%
2019 (partial year)	+39.70%

As of September 4, 2026.

CABA Revenue and Earnings by Fiscal Year

FY ends December

RevenueNet income

2022202320242025

Fiscal year	Revenue	Net income	Net margin
2025	$0.00	−$167.86M	—
2024	$0.00	−$115.86M	—
2023	$0.00	−$67.68M	—
2022	$0.00	−$52.98M	—

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$0.00	—	−$172.24M	−$167.86M	—
2024	$0.00	—	−$125.14M	−$115.86M	—
2023	$0.00	—	−$74.66M	−$67.68M	—
2022	$0.00	—	−$54.14M	−$52.98M	—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

CABA Valuation vs Biotechnology Median

Median of 656 stocks

Metric	CABA	Biotechnology median	vs median
Profit margin	0.00%	0.00%	0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Cabaletta Bio, Inc. (CABA) is capitalised at $588.32M on the latest close. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 154.

The most recent close on file for CABA is $3.47, dated September 4, 2026. That is −$0.01 (−0.29%) against the previous close. The 52-week range on file runs from $1.63 to $4.23. The latest close sits 113.54% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $0.00. The same year closed with a net loss of $167.86M. Profit margin runs at 0%. Trailing earnings per share are −1.38.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

Over the trailing twelve months the price has returned +125.32%. Measured over 5 years, that is −20.69% a year compounded. The reported beta is 3.26. Daily returns over the trailing 6 years annualize to a volatility of 107.11%.

Growth & Income

No dividend is on file for CABA.

The strongest complete calendar year on file is 2023 at +145.41%; the weakest is 2024 at −90.00%. Of the 6 complete calendar years on file, 2 finished higher. So far in 2026 the price is +58.45%.

Peer Comparison

Cabaletta Bio, Inc. (CABA) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
Cabaletta Bio, Inc.	CABA	$588.32M	—
Vertex Pharmaceuticals Incorporated	VRTX	$138.42B	32.5
Regeneron Pharmaceuticals, Inc.	REGN	$85.22B	20.5
argenx SE	ARGX	$64.25B	40.1

The Biotechnology industry average P/E ratio is 12.6x. Cabaletta Bio, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

ARGX

argenx SE

$64.25B

MRNA

Moderna, Inc.

$58.11B

RVMD

Revolution Medicines, Inc.

$45.01B

ONC

BeOne Medicines AG

$40.53B

View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

JNJ

Johnson & Johnson

$663.28B

ABBV

AbbVie Inc.

$453.19B

MRK

Merck & Co., Inc.

$370.89B

UNH

UnitedHealth Group Incorporated

$356.47B

View all Healthcare stocks →

About Cabaletta Bio, Inc.

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. The company's lead product candidate is resecabtagene autoleucel, a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T, which is in Phase 1/2 clinical trials for the treatment of dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, juvenile myositis, lupus nephritis, systemic lupus erythematosus, relapsing and progressive multiple sclerosis, mucocutaneous and mucosal pemphigus vulgaris (PV), systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, a CAAR T cell therapy that is in Phase 1 clinical trial for the treatment of mucosal PV; and MuSK-CAART, an investigational cell therapy in Phase 1 trial for treating patients with anti-muscle-specific kinase (MuSK) antibody positive myasthenia gravis. It has collaborations with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; Autolus Holdings (UK) Limited; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

Visit website →

Cabaletta Bio, Inc. (CABA) Stock Analysis